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Abstract
Purpose Poor sperm quality is a major contributor to infertility in heterosexual couples, but at present there are few empiri-
cal therapies. Several studies have examined the role of dietary factors and data from randomized controlled trials suggest 
that oral antioxidant therapy can improve some sperm parameters. Health beneits of lycopene supplementation have been 
proposed for a variety of health conditions and here we examine whether it can help improve sperm quality. This study aimed 
to investigate the efect of 14 mg daily lactolycopene for 12 weeks on semen quality in healthy men.
Methods Sixty healthy male participants were recruited and randomized to this double-blind, placebo-controlled parallel 
study and received either 14 mg/d lactolycopene or a placebo for 12 weeks. The primary endpoint was a change in motile 
sperm concentration. Secondary endpoints were all other aspects of sperm quality, including the level of sperm DNA damage.
Results Fifty-six men completed the intervention and the level of plasma lycopene was signiicantly increased in the men 
randomized to receive lycopene supplementation. There was no signiicant change in the primary endpoint (motile sperm 
concentration) post-intervention (p = 0.058). However, the proportion of fast progressive sperm (p = 0.006) and sperm with 
normal morphology (p < 0.001) did improve signiicantly in response to lactolycopene intervention.
Conclusions Supplementation with 14 mg/d lactolycopene improves sperm motility and morphology in young healthy men.
Clinical Trial Registry number and website ISRCTN33248724 http://www.isrct n.com/ISRCT N3324 8724
Keywords Lactolycopene · Sperm motility · Sperm morphology · Fertility
Introduction
Current estimates suggest that infertility afects up to 16.7% 
of heterosexual couples in developed countries [1] and it is 
generally recognized that male sub-fertility plays a contribu-
tory role in up to 50% of cases [2]. Typically, fertility prob-
lems in the male manifest themselves as ejaculates contain-
ing too few sperm (oligozoospermia), or sperm that swim 
poorly (asthenozoospermia), or sperm with poor size and 
shape (teratozoospermia) or a combination of all three [3].
Unfortunately, for most sub-fertile men, there are few 
empirical therapies to improve poor sperm quality [4]. As 
such, for most men, healthcare professionals can only focus 
on delivering general advice to highlight the known lifestyle 
risks for poor sperm quality. For example, epidemiologi-
cal studies have shown how certain occupations [5, 6], the 
wearing of tight underwear [7, 8], tobacco smoking [9], high 
body mass index (BMI) [10] and recreational drug use [11] 
are each associated with aspects of poor sperm quality.
Similarly, there is some evidence that dietary factors 
are also correlated with sperm quality, for example, data 
on average daily nutrient intake from food and supplements 
obtained from self-administered food frequency question-
naires found that higher antioxidant intake was associated 
with higher sperm concentration and motility [12]. How-
ever, although over 25 randomized controlled trials to test 
the efect of oral antioxidant supplementation (single or 
combined) versus placebo on semen quality have been con-
ducted, the results are largely inconsistent and inconclusive 
due to their poor quality and high heterogeneity of design 
[13].
Of the many oral antioxidants examined for their efects 
on semen quality, a recent systematic review [14] concluded 
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that diets rich in vitamin E, vitamin C, β-carotene, selenium, 
zinc, cryptoxanthin and lycopene were inversely associated 
with poor sperm quality. Of these, lycopene has had renewed 
interest in other aspects of male reproductive health. For 
example, in a recent study of nearly 50,000 male health pro-
fessionals, dietary lycopene was associated with a reduced 
risk of lethal prostate cancer [15] and a dose–response meta-
analysis of 34 studies suggested that the risk was reduced by 
3% per 1 mg/day increment of dietary lycopene intake [16]. 
There have been only a few trials to date that have directly 
considered the effect of lycopene on semen parameters 
(reviewed in [17]). A few human studies include an open-
label study of 30 men with idiopathic infertility allocated 
to 4 mg lycopene daily for 12 weeks, where improvements 
were seen in sperm concentration, motility and morphology 
in a high proportion of the men [18]. Another study of 50 
oligoasthenozoospermic men prescribed 8 mg of lycopene 
each day for an indeinite period reported the optimisation 
of sperm parameters in 36% of them [19]. A more recent 
study reported a transient improvement in sperm motility 
after 6 weeks in infertile men randomized to a 12-week 
intervention of tomato juice, providing 30 mg lycopene each 
day, compared to a no-intervention control [20]. However, 
the complexity of the tomato juice food matrix, which also 
provided vitamin C and E, makes it diicult to attribute the 
apparent improvement to lycopene alone. The lack of an 
efective placebo control group in each of these studies lim-
its their interpretation and generalisability and highlights the 
need for a randomized placebo control trial.
Therefore, given the clinical interest and potential for 
dietary supplements to improve semen quality, as well as the 
renewed interest in antioxidants and speciically lycopene, 
we reasoned that a randomized controlled trial of lycopene 
supplementation was warranted. In this paper, we, therefore, 
report the outcome of a double-blind, placebo-controlled 
randomized trial to investigate the efect of 3 months of 
oral lactolycopene supplementation on the semen quality of 
healthy male volunteers.
Methods
Healthy male volunteers were recruited from the Sheield 
city region in April and May 2016 using a brief campaign 
conducted by email, social media and lealets targeted at 
(but not limited to) staf and students at the University of 
Sheield (UK). Potential volunteers registered their inter-
est in participating in the study by e-mail and subsequently 
underwent a telephone eligibility screening. Men were 
excluded if they had previous testicular surgery, existing or 
previous cancer, or if they had a known allergy to tomato, 
whey protein or soy derivatives. Otherwise, they were sent 
an information sheet and invited to an enrolment visit if 
they were (i) aged between 18 and 30 years; (ii) lived 
within 1 h of the Royal Hallamshire Hospital, Sheield; 
and (iii) were planning to live in the Sheield city region 
for the duration of the study. The primary outcome of the 
study was motile sperm concentration, and secondary out-
comes were sperm volume, concentration, motility, mor-
phology, DNA damage and plasma lycopene concentration 
measured at baseline and end of intervention (week 12). 
There were no robust data on which to base a sample size 
calculation. The data provided by Gupta et al. (2002) [18] 
could not be used for a formal power calculation due to 
their reporting method. Thirty infertile men were recruited 
in that study, but data were only reported for the men that 
showed an improvement for one of the sperm parameters 
(n = 20 for sperm concentration) and means (± SD) were 
not provided for the whole population. Nevertheless, this 
paper did provide an indication of the likely sample size 
required, and on this basis, we aimed to recruit 30 partici-
pants per treatment arm.
At the enrollment visit, men were given the opportunity 
to ask further questions and, if they agreed to participate, 
invited to sign a consent form. Then basic demographic 
variables were recorded, and men completed a brief ques-
tionnaire about their lifestyle choices (e.g. smoking habits, 
alcohol consumption and choice of underwear). In addition, 
their height and weight were recorded, and their BMI was 
calculated in kg/m2. A date was then agreed for them to start 
the study and attend the follow-up visits in weeks 6 and 12 
of the study, respectively.
The study design was a randomized, double-blind, 
placebo-controlled trial and at the irst visit, men were 
randomly allocated to either treatment or placebo groups 
using a block randomisation schedule in blocks of four. 
The randomisation code was created using a randomiza-
tion generator (www.rando mizat ion.com) and held by a 
third party until all analysis was complete, and all capsules 
were identically boxed to ensure both the researchers and 
volunteers were blind to the allocation. The lactolycopene 
supplement was manufactured and provided by Cambridge 
Nutraceuticals Ltd. (Cambridge, UK) who also provided 
the placebo. The supplement was supplied in capsule form 
and provided 7 mg lycopene per capsule within a whey 
protein matrix formulated to enhance lycopene absorption 
[21]. The placebo capsules were identical in appearance 
but contained microcrystalline cellulose. Participants were 
instructed to take two capsules per day with water (one in 
the morning and one in the evening) for 12 weeks (May to 
September 2016). Compliance was calculated on the basis 
of number of capsules returned at the end of the study as 
a percentage of the number of capsules expected to have 
been consumed during the intervention period.
All participants were asked to provide a semen sample 
(after 3 days of sexual abstinence) at the irst (baseline) 
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visit and also at the follow-up appointment arranged in 
week 6 and at the end of the study (week 12). In the 7 days 
prior to each visit, men were supplied with a pre-weighed 
sterile container (Sarstedt, Leicester, UK), reminded of 
the abstinence period and asked to record the time of 
production and deliver the semen sample to the labora-
tory within 1 hour. Upon arrival, the sample was analysed 
according to World Health Organisation (2010) methods 
and, in addition, sperm motility was assessed using ver-
sion 5.0 of the Sperm Class Analyzer (Microptic SL, Bar-
celona, Spain) attached to a Microtec LM-2 Microscope 
(Mazurek Optical Services Ltd, Southam, UK) via a Basler 
A312fc camera (Basler AG, Ahrensburg, Germany) [22]. 
This assigned each sperm observed in one of four motil-
ity grades: (i) fast-progressive (≥ 25 µm per second), (ii) 
slow-progressive (≥ 5 and < 25 µm per second), (iii) non-
progressive (< 5 µm per second), and (iv) immotile (0 µm 
per second). Slides were also prepared for the assessment 
of sperm DNA fragmentation by TUNEL according to the 
methods published previously [23].
At each study visit, 5 ml of non-fasting blood was col-
lected by venepuncture into EDTA tubes (BD Bioscience, 
Wokingham, UK). Blood samples were centrifuged immedi-
ately (400 g for 10 min) to separate the plasma and red blood 
cells. Plasma was stored in light-protected Eppendorf tubes 
(BD Bioscience, Wokingham, UK) and frozen at − 70 °C 
prior to analysis. Plasma lycopene concentrations were ana-
lysed by reverse-phase HPLC with ultraviolet detection [24] 
at the Department of Clinical Biochemistry, Glasgow Royal 
Inirmary.
Dietary intake was assessed at baseline and at the end 
of the intervention using a 4-day food diary (including 1 
weekend day) as previously outlined [25]. Food portion 
sizes were veriied by an interview with the researcher (AR) 
using the Ministry of Agriculture Food and Fisheries food 
atlas [26]. The 4-day estimated food diary was analysed for 
macronutrient and micronutrient content using WinDiets 
Research software (version 2016; Robert Gordon University, 
Aberdeen, United Kingdom).
All statistical analyses were performed in SPSS (Ver-
sion 25). Data were checked for normality using the Sha-
piro–Wilk test. Baseline diferences between the groups 
were examined using unpaired t tests and Mann–Whitney 
U tests as appropriate. Within the group, changes from 
baseline were analysed using paired t tests and Wilcoxon 
signed-rank test. Categorical data were analysed using Chi-
squared analysis. Many of the nutrient variables were not 
normally distributed and so non-parametric tests were used 
to analyse the data.
Ethical approval for the study (including the meth-
ods of enrolment) was obtained from the University of 
Sheffield’s Medical School Research Ethics Committee 
(SMBRER008135). The trial was registered at http://www.
isrct n.com/ as ISRCTN33248724 and was conducted in 
accordance with the Declaration of Helsinki. Participants 
who completed the study received a £75 voucher to com-
pensate them for their time and efort and to cover travel 
expenses.
Results
A total of 141 men responded to the recruitment campaign 
and expressed their interest in participating in the study. 
However, after being sent the information sheet, 39 decided 
not to continue and, after the initial telephone interview, 22 
did not meet the inclusion criteria (see Fig. 1). Therefore, 
80 men were invited to participate of which 70 signed a 
consent form at the enrolment visit and 60 attended the irst 
appointment and provided a baseline semen analysis and 
blood sample. Four men withdrew from the study before 
the end, two from each arm of the study. No adverse events 
were reported by any of the participants. The duration of 
the intervention was similar in both treatment arms with a 
median duration of 84 days in both treatment arms (Table 1). 
Fifty of the 56 men who completed the trial returned their 
unused capsules at the end of the study. Compliance with the 
intervention was good and similar in both treatment arms, 
with median compliance of 97.6% and 94.3% in the placebo 
and lactolycopene arms, respectively (Table 1).
Table 1 also shows the demographic characteristics of the 
56 men who completed the study. Briely, the mean ± SD age 
of the participants was 23.3 ± 2.89 years (range 19–30 years) 
and there was no signiicant diference between those ran-
domized to placebo or lactolycopene, nor was there a sig-
niicant diference between the proportion of smokers, street 
drug use, or choice of underwear, in either group. However, 
the mean ± SD BMI of men randomized to receive lactoly-
copene was signiicantly higher than those randomized to 
placebo (25.2 ± 3.08 vs 23.5 ± 3.11; p = 0.049). There was 
a wide range in habitual self-reported alcohol intake in the 
population with intakes ranging from 0 to 40 units per week, 
but the proportion of no/moderate and high consumers was 
similar in both treatment arms. Critically, there was no dif-
ference in plasma lycopene levels in either group at the start 
of the study.
Table 2 shows the semen quality data at baseline and 
shows the various measures were well balanced with no sta-
tistical diferences between men taking lactolycopene versus 
placebo for any semen variable. Table 3 shows the levels of 
plasma lycopene, semen quality and clinical classiication 
at the beginning and the end of the intervention. Briely, 
whilst there was no change in the primary outcome measure 
of motile sperm concentration in either group, in the lactoly-
copene arm there was a signiicant increase in the percent 
of fast-progressive sperm (10.6 ± 8.75 vs 14.76 ± 10.29; 
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p = 0.006), the percent of morphologically normal sperm 
(7.5 ± 5.49 vs 13.5 ± 4.90; p < 0.001) and in the plasma lyco-
pene concentration (0.645 ± 0.226 vs 0.751 ± 0.221 µmol/l; 
p = 0.020) when the baseline measurement was compared to 
that obtained in week 12. In contrast, the only change in the 
placebo arm of the study was a statistical decrease in the per-
cent of non-progressive sperm (24.6 ± 6.67 vs 21.4 ± 6.53; 
p = 0.002). Over the 12 weeks of study, there was no change 
in the percent of sperm with DNA damage. There was no 
signiicant diference at week 12 between the lactolycopene 
and placebo treatment arms for any of the semen quality 
parameters measured (p values not shown in table, all exceed 
0.05; NS).
Energy and nutrient intake at baseline and at the end 
of intervention for the two arms of the study are shown in 
Table 4. There were no signiicant diferences between the 
groups at baseline and no signiicant change in dietary intake 
in response to treatment in either arm. Dietary intake was not 
signiicantly diferent between treatment arms at week 12 (p 
values not shown in table, all exceed 0.05; NS).
Discussion
Lycopene is a carotenoid found in high concentrations in 
tomatoes, tomato products and other red-pigmented foods 
which has received considerable interest in recent years as 
a potential therapeutic agent for a variety of health condi-
tions [27]. However, the bioavailability of lycopene from 
fresh tomatoes is low, but this is enhanced by processing, 
heating and co-delivery of tomatoes with oil [28]. As such, 
this study used the nutritional supplement lactolycopene, 
the main ingredient of which is lycopene embedded in a 
whey protein matrix for enhanced intestinal absorption. 
The 14 mg/d of lactolycopene supplied to the men in this 
study is equivalent to consuming 2 kg of cooked toma-
toes or 2 tablespoons of concentrated tomato puree each 
Fig. 1  Consort low chart of study. CONSORT consolidated standards of reporting trials
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day, and so represented a sizable increase in the lycopene 
intake of the study participants.
For this study, we chose to enrol as our study participants 
young healthy volunteers with no known fertility issues. 
However, this was done with the knowledge that a sizeable 
proportion of them would have poor sperm quality at the 
outset [29] but since they were less likely to have tested their 
fertility and they were not actively trying to conceive, they 
Table 1  Baseline characteristics, duration of intervention and compliance with the intervention in the participants who completed the study
Mean ± SD (all such values) unless otherwise stated p: independent sample t test for continuous variables unless otherwise stated; Pearson’s Chi-
square test for categorical variables
a Non-parametric Mann–Whitney U
b 2 of the participants in the placebo arm had missing plasma lycopene at baseline
c Compliance was calculated as the total number of capsules returned as a percentage of the number of capsules expected to be consumed during 
the intervention period
Characteristic All
(n = 56)
Placebo
(n = 28)
Lactolycopene (n = 28) p
Age (years) 23.3 ± 2.89 23.3 ± 2.58 23.4 ± 3.22 0.855
Smokers (n) 8 4 4 1.0
Street drug use
Yes [n (%)] 4 (7%) 2 (7%) 2 (7%) 1.0
No [n (%)] 52 (93%) 26 (93%) 26 (93%)
Underwear type (n)
Tight 34 17 17 1.0
Loose 22 11 11
BMI (kg/m2) 24.4 ± 3.18 23.5 ± 3.11 25.2 ± 3.08 0.049
Alcohol consumption units/w [median (min–max)]a 8 (0–40) 7 (0–28) 10 (0–40) 0.136
Plasma lycopene (µmol/l)b 0.666 ± 0.255 0.689 ± 0.286 0.645 ± 0.226 0.532
Number of intervention days [median (IQR)] 84 (1.0) 84 (1.0) 84 (1.75) 0.545
(n = 50) (n = 26) (n = 24)
Percent compliance [median (IQR)]c 95.8 (9.23) 97.6 (8.48) 94.3 (10.57) 0.219
Table 2  Baseline semen 
quality (mean ± SD) of 
men randomized to receive 
lactolycopene or placebo
p: independent sample t test or aNon-parametric Mann–Whitney U for continuous variables
b Expressed as the concentration of fast-progressive and slow-progressive sperm
c Pearson chi squared
All
n = 56
Placebo
n = 28
Lactolycopene
n = 28
p
(a) Semen quality
Abstinence (d)a 3.2 ± 0.82 3.1 ± 0.54 3.3 ± 1.02 0.248
Semen volume 4.1 ± 1.66 4.0 ± 1.57 4.2 ± 1.77 0.635
Sperm concentration (× 106/ml)a 63.4 ± 50.79 56.8 ± 43.24 70.0 ± 57.40 0.523
Percent motility (%) 61.1 ± 23.78 62.8 ± 22.69 59.4 ± 25.13 0.597
Fast progressive (%) 11.2 ± 7.76 11.8 ± 6.96 10.6 ± 8.57 0.551
Slow progressive (%) 24.9 ± 14.51 26.3 ± 14.74 23.5 ± 14.40 0.474
Non-progressive (%) 25.0 ± 7.63 24.6 ± 6.67 25.3 ± 8.58 0.752
Immotile (%) 38.9 ± 23.79 37.2 ± 22.68 40.6 ± 25.14 0.598
Motile sperm concentration (× 106/ml)b 27.0 ± 31.03 26.2 ± 31.68 27.8 ± 30.93 0.597
Sperm with normal morphology (%)a 8.3 ± 5.40 9.1 ± 5.28 7.5 ± 5.48 0.144
DNA damage (%)a 1.5 ± 1.56 1.4 ± 1.65 1.6 ± 1.48 0.366
(b) Clinical classificationc
Normozoospermic (n) 25 14 11 0.420
Other (n) 31 14 17
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Table 3  Plasma lycopene and semen quality (mean ± SD) and clinical classiication (n) of baseline versus week 12 for men randomized to 
receive placebo or lactolycopene supplementation
a 2 of the participants in the placebo arm had missing plasma lycopene at baseline and 1 had missing plasma lycopene at week 12
p: paired t test or bWilcoxon signed-rank test for continuous variables
c Expressed as the concentration of fast-progressive and slow-progressive sperm
d Cochran Q test; 1 of the participants in the lactolycopene arm had missing sperm motility and motile sperm concentration data at week 12
Placebo arm (n = 28a) Lactolycopene arm (n = 28a)
Variable Baseline Week 12 p Baseline Week 12 p
Plasma lycopene (µmol/l) 0.689 ± 0.286 0.719 ± 0.306 0.563 0.645 ± 0.226 0.751 ± 0.221 0.020
Semen quality:
Abstinence (d)b 3.1 ± 0.54 3.5 ± 1.11 0.102 3.3 ± 1.02 4.4 ± 5.11 0.393
Semen volume (ml) 4.0 ± 1.57 4.1 ± 2.56 0.873 4.2 ± 1.77 3.7 ± 1.57 0.116
Sperm concentration (× 106/ml)b 56.8 ± 43.24 62.8 ± 55.10 0.569 70.0 ± 57.40 67.6 ± 52.47 0.81
% Motility 62.8 ± 22.69 59.3 ± 26.53 0.332 59.4 ± 25.13 64.3 ± 21.79 0.205
% Fast progressive 11.8 ± 6.96 12.5 ± 7.90 0.696 10.6 ± 8.57 14.76 ± 10.29 0.006
% Slow progressive 26.3 ± 14.74 25.5 ± 17.35 0.690 23.5 ± 14.40 24.92 ± 11.43 0.491
% Non-progressive 24.6 ± 6.67 21.4 ± 6.53 0.002 25.3 ± 8.58 24.6 ± 7.33 0.649
% Immotile 37.2 ± 22.68 40.7 ± 26.53 0.333 40.6 ± 25.14 35.7 ± 21.79 0.206
Motile sperm concentration (× 106/ml)b,c 26.2 ± 31.7 29.6 ± 37.5 0.509 27.8 ± 30.9 31.3 ± 30.3 0.058
Sperm with normal morphology (%)b 9.1 ± 5.28 11.3 ± 6.6 0.124 7.5 ± 5.49 13.5 ± 4.90 <0.001
% DNA  damageb 1.4 ± 1.65 1.5 ± 2.25 0.366 1.6 ± 1.49 2.1 ± 3.21 0.476
Clinical  classiicationd
Normozoospermic (n) 14 13 0.763 11 18 0.052
Other (n) 14 15 17 9
Table 4  Energy and nutrient 
 intakea at baseline versus 
week 12 for men randomized 
to receive placebo or 
lactolycopene supplementation
a Energy and nutrients derived from the diet and non-intervention supplements
b Non-parametric Mann–Whitney U was used to compare dietary intake between the groups at baseline and 
end of intervention. No signiicant diferences were found
c Wilcoxon signed-rank test was used to examine within group change from baseline. Data are presented as 
medians (IQR)
Placebo arm (n = 28) Lactolycopene arm (n = 28)
Variable Baselineb Week  12b pc Baselineb Week  12b pc
Energy (kJ/d) 9327 (2609.8) 9871 (3290.5) 0.964 9614 (3737.3) 10,997 (6425.8) 0.265
Energy (kcal/d) 2178 (755.0) 2358 (779.3) 0.982 2252 (854.5) 2617 (1525.0) 0.295
Protein (g/d) 91.5 (53.2) 92.8 (33.3) 0.425 96.0 (46.5) 107.3 (80.8) 0.412
Fat (g/d) 88.5 (56.3) 89.8 (44.7) 0.982 93.1 (47.6) 93.3 (63.9) 0.295
Saturated fat (g/d) 31.4 (16.8) 28.4 (17.6) 0.554 28.9 (18.5) 35.6 (23.0) 0.172
Carbohydrate (g) 254 (126.6) 233 (89.3) 0.767 245 (70.5) 247.8 (156.1) 0.767
Dietary ibre (g/d) 17.7 (9.2) 17.2 (11.4) 0.539 20.0 (10.9) 18.1 (13.6) 0.973
Alcohol (g/d) 8.95 (23.1) 4.6 (23.0) 0.931 6.7 (28.4) 5.4 (23.4) 0.615
Vitamin A (µg/d) 556 (490.8) 757 (55.8) 0.452 685 (886.5) 617 (462.8) 0.699
Vitamin C (mg/d) 70.7 (74.5) 81 (69.1) 0.480 72.2 (72.8) 65.1 (96.3) 0.227
Vitamin E (mg/d) 11.3 (6.21) 10.3 (6.76) 0.909 11.4 (5.77) 10.2 (6.53) 0.716
Zinc (mg/d) 10.8 (5) 9.8 (4) 0.531 10.4 (6.5) 12.7 (5.3) 0.585
Selenium (µg/d) 62.5 (37.5) 54.0 (31.8) 0.344 51.5 (32.8) 69.5 (49.0) 0.096
Retinol (µg/d) 310 (168.5) 296 (268.3) 0.649 305 (351.5) 337 (203.3) 0.327
Carotene (µg/d) 1507 (2823.5) 1500 (3789.8) 0.820 1844 (3691.8) 1291 (2163.5) 0.509
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would be blind to their own semen quality (unlike fertility 
patients attending a clinic) and, therefore, unlikely to make 
other adjustments to their lifestyle to enhance fertility. It 
is noteworthy that at the outset of the study, 31 of the 56 
men (see Table 3) did not have normal semen parameters 
(normozoospermia), suggesting that our original assump-
tion was correct.
For the primary outcome measure, we chose to use the 
concentration of motile sperm since this has been shown to 
be the variable obtained from semen analysis most likely 
to be associated with the probability of conception [30]. 
However, whilst this was not statistically improved after 
lycopene supplementation (p = 0.058) two other measures 
of sperm quality were signiicantly altered: (i) the proportion 
of fast-progressive sperm (p = 0.006) and (ii) the proportion 
of sperm with normal morphology (p < 0.001). The direction 
of both these changes is positive, but it is impossible to say 
how they might impact chances of natural pregnancy or the 
choice of assisted reproduction treatment (ART) had our 
participants been attending an infertility clinic. In theory, 
both are clinical improvements in sperm quality and would 
presumably be welcomed by infertile men. Whilst many 
measures of sperm motility [31, 32] and morphology [33] 
are di cult to make, we used computer-assisted sperm anal-
ysis for both measures, which provides a level of objectivity; 
furthermore, the sperm quality measures were performed 
blind to the allocation of each participant. In comparison to 
the changes observed in the men randomized to lycopene 
supplementation, the only statistically signiicant change 
observed in the placebo group was a reduction in the per-
cent of non-progressive sperm (p = 0.002). We are unable 
to explain this observation but conclude that it is unlikely to 
be clinically signiicant since it was only accompanied by 
a non-signiicant increase in the percent non-motile sperm, 
and sperm with these motility characteristics are unlikely to 
participate in natural conception [2]. Interestingly, we saw 
no change in sperm DNA damage, but given the ongoing 
controversy about its measurement and interpretation [34] 
this is perhaps not surprising.
The 12-week duration of the study was chosen to increase 
plasma lycopene levels across the full (~ 70 day) window 
required to make (and ejaculate) new sperm [35] because we 
did not want to make any assumptions about when lycopene 
supplementation might be most beneicial. Therefore, it is 
not possible to conclude whether there is an optimum dura-
tion of lycopene supplementation that would give the same 
results as those reported here without undertaking further 
study.
Similarly, the choice of lactolycopene dose was a prag-
matic one based on the availability of the supplement from 
the supplier, and the use of similar lycopene dosages and 
durations in clinical trials of cardiovascular disease [36]. 
So, again, we are unable to comment whether diferent doses 
of the supplement to the ones used here may lead to the 
same results. However, it is noteworthy that the results we 
describe are similar to those previously reported in an open-
label study showing improvements in sperm morphology 
and motility using 4 mg of daily lycopene supplementation 
for 3 months [18]. The daily dose of 14 mg lycopene was 
certainly able to signiicantly increase the plasma lycopene 
level in our study participants (see Table 3) compared to 
those randomized to placebo. However, whether this is the 
optimum level to maximize any efects on sperm quality 
measures remains to be established.
The underlying biological mechanism of action whereby 
lycopene exerts an efect on the sperm is currently unknown. 
The antioxidant properties of lycopene have been the pri-
mary focus of mechanistic investigation of the action of 
lycopene on idiopathic male infertility to date [17]. Oxida-
tive stress is believed to play a role in the pathogenesis of idi-
opathic male infertility and although reactive oxygen species 
play an important role in normal sperm function, disequi-
librium of reactive oxygen species and antioxidant defence 
appears to be detrimental [37]. While it is well known that 
sperm are very vulnerable to damage by free radicals [38], 
we cannot assume that the beneicial efects of lycopene we 
observed are because of its antioxidant properties as we did 
not make any relevant measurements of oxidative stress in 
biological luids such as seminal plasma. However, an anti-
oxidant role for lycopene is a plausible hypothesis.
The study reported here had a modest sample size and 
is not without its limitations. First, to increase the rates of 
compliance by the study participants, we allowed them to 
produce their samples at home rather than in a clinic and 
this would have inevitably led to a delay in undertaking 
some of the measurements we have reported here. How-
ever, the World Health Organisation Laboratory Manual 
for the examination and processing of human semen [3] 
recommends that all measurements be performed within 
1 h of sample production and others [39] have argued that 
specimen collection at home is not detrimental as long 
as samples are delivered in a timely manner and motil-
ity measurements are done at the correct temperature. In 
this study, the median delay in processing the samples 
was 58.5 min (range 35–115 min) and was not diferent 
between those men randomized to lycopene vs placebo. 
Furthermore, all motility measurements were undertaken 
at 37 °C as per WHO (2010) recommendations. Second, 
it is known that BMI is related to aspects of semen qual-
ity [10] and although the majority of the study partici-
pants had a normal BMI, a high proportion (45%) fell 
in the overweight or obese category. This may relect a 
high muscle mass rather than a high fat mass since a pro-
portion of the men were recruited via University Sports 
clubs. Interestingly, the BMI of men randomized to lyco-
pene was signiicantly higher (p = 0.049) compared to 
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those randomized to placebo (Table 1) which suggests 
that the observed improvement in semen quality in these 
men could be more remarkable than in men with a lower 
BMI. However, the diference in BMI is small and prob-
ably biologically insigniicant, although in future studies 
it could be useful to consider undertaking an analysis of 
body composition using bioelectrical impendence [40] for 
a more accurate assessment of percentage body fat.
In conclusion, we report a modest but statistically sig-
niicant improvement in the semen quality of healthy young 
men randomized to receive 14 mg lactolycopene per day 
for 12 weeks. Whilst the study demonstrates improvements 
in some measures of sperm quality in response to lycopene 
supplementation, the clinical impact on fertility and the 
chances of pregnancy, and live birth are unknown. Future 
studies should focus on men from infertile partnerships to 
determine not only the optimum dose and timing of lyco-
pene both to improve sperm quality but also whether this 
enhances pregnancy outcome for these couples.
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